Stem Cell Transplant Complications Clinical Trials

19 recruiting

Stem Cell Transplant Complications Trials at a Glance

19 actively recruiting trials for stem cell transplant complications are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Beijing, Boston, and Calgary. Lead sponsors running stem cell transplant complications studies include Peking University People's Hospital, Dana-Farber Cancer Institute, and Pierre Fabre Medicament.

Browse stem cell transplant complications trials by phase

Treatments under study

About Stem Cell Transplant Complications Clinical Trials

Looking for clinical trials for Stem Cell Transplant Complications? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stem Cell Transplant Complications trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stem Cell Transplant Complications clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354
Recruiting
Not Applicable

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

Sexual DysfunctionStem Cell Transplant ComplicationsBone Marrow Transplant Complications
Massachusetts General Hospital300 enrolled3 locationsNCT06541002
Recruiting

Intestinal Microbiota in Stem Cell Transplant Transplant Admission

Stem Cell Transplant Complications
Henry Ford Health System255 enrolled1 locationNCT04623424
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

Loratadine for the Prevention of G-CSF-related Bone Pain

Stem Cell Transplant Complications
AHS Cancer Control Alberta78 enrolled1 locationNCT05421416
Recruiting
Not Applicable

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Multiple MyelomaStem Cell Transplant Complications
Dana-Farber Cancer Institute30 enrolled2 locationsNCT05706766
Recruiting
Phase 2

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

GVHD,AcuteStem Cell Transplant Complications
Daihong Liu168 enrolled1 locationNCT07340723
Recruiting
Phase 1

IS-free Treg HaploHCT

Stem Cell Transplant Complications
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Phase 3

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Stem Cell Transplant ComplicationsEBV InfectionCMV Infection+1 more
Tobias Feuchtinger149 enrolled33 locationsNCT04832607
Recruiting
Not Applicable

Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients

Sleep DisturbanceStem Cell Transplant Complications
Dana-Farber Cancer Institute10 enrolled2 locationsNCT06468618
Recruiting
Phase 2

ATG Individualized Dosing Model in URD-PBSCT.

Stem Cell Transplant ComplicationsCytomegalovirus InfectionsInfection Reactivation
Chinese PLA General Hospital30 enrolled1 locationNCT06572462
Recruiting
Not Applicable

Modified Second Haplo-transplantation for Graft Failure

Stem Cell Transplant ComplicationsGraft Failure
Peking University People's Hospital12 enrolled1 locationNCT06512545
Recruiting
Not Applicable

Second Haplo-transplantation for Graft Failure

Stem Cell Transplant ComplicationsGraft Failure
Peking University People's Hospital34 enrolled1 locationNCT06512519
Recruiting
Phase 2Phase 3

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

ThrombocytopeniaStem Cell Transplant Complications
Peking University People's Hospital142 enrolled14 locationsNCT06202625
Recruiting
Not Applicable

Early Integration of Palliative and Supportive Care in Cellular Therapy

Multiple MyelomaLymphomaLeukemia+3 more
Alberta Health Services, Calgary152 enrolled1 locationNCT05190653
Recruiting

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Hematologic MalignancyStem Cell Transplant Complications
Peking University People's Hospital20 enrolled1 locationNCT05921318
Recruiting
Phase 2

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic MalignancyStem Cell Transplant Complications
First Affiliated Hospital of Zhejiang University95 enrolled1 locationNCT04809181
Recruiting
Phase 2Phase 3

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Stem Cell Transplant ComplicationsLeukemia, Myeloid, AcuteLeukemia Relapse
Peking University People's Hospital55 enrolled1 locationNCT03793517